Skip to main content

Immunic, Inc Investor Event Transcript, Nov 9, 2026

Immunic, Inc. (IMUX)

Immunic expects Ensure 1 and Ensure 2 to read out in December; positive results could support an NDA filing and approval in relapsing multiple sclerosis, with filing targeted for the middle of next year. AI summary

Investor Event Transcript 2026-11-09 For: 2026-12-31
Added on November 10, 2026

Conference Transcript - IMUX 2026-11-09

Yatin Suneja, Analyst — Guggenheim

All right. Good afternoon, everyone. Welcome to Guggenheim's third annual healthcare innovation conference. My name is Yatin Suneja, one of the biotech analysts here at the firm. It is my pleasure to introduce our next presenting company in Munich. From the company, we have two executives here. We have Eric Lundgren, who's the chief executive officer, and then we have Jason Tardio, who's the president and chief operating officer. Eric, I'm going to pass it on to you, maybe perhaps make some opening comments, tell us about what we should be focused on in the next, let's say, few months or so, and then we'll go into some of the Q&A that I've prepared for you.

Erik Lundgren, CEO

Yeah, for sure. Thanks for having us, first of all. I think it's a really exciting time for us. We have two pivotal trials reading out in December. So we're right around the corner, right on the threshold of that data. These are two studies called Ensure 1 and Ensure 2, and they would, if they're positive, result in an NDA filing and approval in relapsing multiple sclerosis. So I'd say our priorities really are preparing for that readout, building the commercial launch apparatus and infrastructure to support it. And then we just announced last week, progressive MS study, a third pivotal trial in progressive MS called the Protect MS study that we're initiating right now, expecting the first patient in in the first half of next year.

Yatin Suneja, Analyst — Guggenheim

Got it. Maybe first question is on the corporate side and the commercial side. So you just joined recently, right, Eric? And then you have a new CMO. There's a board chair. Jason, you've been here for a while. So maybe just talk about how are you building from a corporate standpoint? How should we think about the commercial angle? Because, you know, if the data are positive, you could be filing NDA and you could be pretty close to commercial relatively soon. So talk about those two companies. Yeah.

Erik Lundgren, CEO

I mean, I think I joined in June. I joined following 19 years at Genentech Roche. I got sort of, the reason I'm probably here is I was a part of launching Ocrelizumab, which is the most prescribed MS medicine in the world today. And it was quite an experience to transform the MS market with the introduction of anti-CD20s. That was a decade ago, though. And I I think I came because the unmet needs today are extremely clear in MS. They're as clear today as they were then, and I think the market is ripe for disruption again, and that's where I think this is allowing us to sort of lean in. And as you said, I mean, I'm not the only new person. Our board, not only our board chair, multiple board members have turned over. We've had the ability to bring in a bunch of executive and team-level talents, which is really a reflection of this pivot from a development stage to pre-commercial stage company. And I'd say that's, and with the board changes, the remit strategically has also become CRISPR, which is about, this is an MS company focused on commercializing our lead asset. And that's where we are.

Yatin Suneja, Analyst — Guggenheim

Jason, how about you?

Jason Tardio, COO

Yeah, from a commercial perspective, we're actively preparing. Once we have successful data in December, it will be an accelerated effort to scale and ramp the company. But we're not waiting for that. We've put a lot of work in place to validate our initial strategic assumptions around go-to-market strategy. We've begun to hire key leadership roles on the commercial side of the business, a VP of marketing. Today, we just had a new vice president of patient advocacy start at the company. We've built out the medical affairs organization and begun to deploy a series of medical science liaisons that are out there educating the market. So we're doing a lot of work now, and of course, you know, if we have successful data in December, we'll accelerate those efforts.

Yatin Suneja, Analyst — Guggenheim

Got it. Very good. Very helpful. Then let's just talk about the product or vitaphylamis. What is the mechanism? I think one part of the mechanism, I think investors and even the physician community know, but it's the neuroprotective side of it, which is the new one activation. It's not very well known. What do you get a sense, like how familiar are sort of KOLs with this mechanism?

Erik Lundgren, CEO

I'd say KOLs are quite excited about the Neur1 activation side of our story. Just to sort of back up, though, Vitaflutemis calcium is a once daily oral tablet. And it really has two underlying mechanisms, as you said, Yadin. There's DHO-DH inhibition, which is a proven pathway in relapsing MS. We're going to talk about the neuroinflammatory side, but there's really nothing approved today that's neuroprotective, and that's where Neur1 comes in. Neur1 upregulates a series of genes that are associated with neuronal repair resilience and survival, and if you understand the underlying disease mechanism in MS, there's sort of two underlying processes. One is sort of an autoimmune or neuroinflammatory disease component, hyperactive T and B cells, effectively. That's what everything approved in MS targets, either through modulation or suppression. Nothing is working on neurons directly, and nothing is really working in the CNS compartment directly. And that's where the NER1 piece of beta flutumous calcium comes into play. So if approved, we'd be the only therapy that is working directly on neurons. And the largest unmet need in MS today are medicines that create a meaningful impact on disability progression. And to do that effectively, you need to reach beyond relapse control and MRI control. You need to sort of get into that neuroprotective space. And Vita Fluminous Calcium is a great shot on goal at that.

Yatin Suneja, Analyst — Guggenheim

All right. What sort of preclinical and clinical evidence you've produced to sort of prove this new one activation thesis?

Erik Lundgren, CEO

Yeah. So we have got a huge set of preclinical data. We shared some of it at the MS meeting in Toronto just a few weeks ago. But, you know, we're very confident. We're binding to activating Neuro1. We can see this in vivo and in vitro models. You can see neuronal survival against challenge. You can see that that effect goes away when you knock out NER1. So we're very confident that this is a direct NER1 component as opposed to the DHODH sort of piece of our mechanism. So we have a quite robust set of preclinical findings. But I think the piece that gets us most exciting is actually in the clinical findings. So from our, we had a phase two study in progressive MS, which was called the caliper study. Relatively large Phase II study, 467 patients, and while it wasn't powered for clinical outcomes, the clinical outcomes on progression, both in terms of slowing the worsening of the disease, but also patients improving on their disability, was very interesting and very compelling to us, especially in a patient population that has had no evidence of neurological So this is sort of the holy grail in MS drug development at the moment is being able to move the needle in that hardest to treat population. And we saw some very exciting, I wouldn't say they're confirmatory of anything. It's phase two findings, nominal, all that stuff. But it gives us confidence going into a phase three study to prove it out.

Yatin Suneja, Analyst — Guggenheim

Got it, got it. So then, with regard to the phase three studies that are going to read out relatively soon, can you maybe recap the design? How are they powered? What are the benchmarks that we need to be paying attention to?

Erik Lundgren, CEO

Yeah, so they're kind of twin studies, so the same exact protocol running sort of on parallel tracks. They read out at the same time, in SURE 1 and 2. In total, we're talking about 2,221 patients, so massive studies, really large. 30 mg dose once daily of Vita flutemis calcium versus placebo, and the primary endpoint is time to first relapse, so it's a relapse study, and then there's a, you know, a series, the normal slate of MRI and other relapse related endpoints, and then we pool the studies to look at a bunch of progression related endpoints.

Yatin Suneja, Analyst — Guggenheim

Got it. How would you characterize like a win here? What would you need to And maybe if you want to recap the emphasis of what you saw in the emphasis.

Erik Lundgren, CEO

So emphasis was our phase two study in relapsing disease, 260. Some odd patients. And, I mean, the answer, we haven't guided to a specific number for the insurer, but I would love to recapitulate what we saw on emphasis. We saw a 42% risk reduction on relapse in that study, and we saw a very compelling safety and tolerability profile. And we've even asked about that, but I mean, safety and tolerability really are essential components of treatment selection in MS. It's impossible to overstate how meaningful that is. It's a chronic disease. Neurologists are typically quite conservative. Thank you. Thank you. There are... There are limitations on that side of the equation for everything that's approved today in MS. So it's a huge area of white space for differentiation on safety and tolerability.

Yatin Suneja, Analyst — Guggenheim

Yeah, since you, I mean, I'll come back to efficacy, but since you touched on the safety so we can address that, I mean, I think if you see the data across all the patients, it seems very benign from a safety standpoint, but when you see the higher efficacy orals, you know, they have either tolerability issues or, let's say, the BTKs. So maybe both of you talk about the profile that you expect, and then from a commercial standpoint, if BTKs come on the market, how will the safety differentiation shake out?

Erik Lundgren, CEO

Yep. Let me start, and then I'll let Jason handle the differentiation. I think from a safety perspective, we have a pretty robust safety database, 3,500-odd patients. Some folks have been on for up to seven years. So for where we are in development, I'd say quite a robust read. I'd also note that, you know, a placebo-controlled study is the highest bar you can possibly set on safety and tolerability, and as you said, I joined the company in June. The first thing I looked at when I was doing my due diligence on the company was the safety and tolerability, and I've seen everything in MS for the last dozen years or so, and I've never seen anything like this, and it's quite impressive. It takes care of a bunch of early sort of knock on wood somewhere. Thus far, we don't see Any evidence of many of the either tolerability or serious safety issues that have plagued MS treatments. So, we see a very clean liver profile. We see a very, very clean infection profile. We don't see anything at all in terms of GI tox issues that are so prevalent with MS treatments today and lead to so much discontinuation of therapy. Abagio, or teraflunamide, which is also a DHO-DH inhibitor, but is sort of a first-generation version, has a bunch of off-target effects that are quite limiting, alopecia, embryo-fetal tox, a bunch of things, some liver issues as well. All of those seem to have been cleaned up with the chemistry, and I think that sets us up with, again, a highly differentiated profile.

Jason Tardio, COO

Yeah, I think what I would add there is if you look across the oral disease-modifying therapy class, to Eric's point, there's benefit-risk tradeoffs. And so what we think fetal flutumous calcium may offer to the market is the best-in-oral class benefit-risk. And that's versus the currently marketed products and certainly versus any potential BTK inhibitor that may or may not make it to the market. And I should remind you that it's a very sizable portion of the market. The oral class still makes up roughly 25% to 30% of all prescriptions. And so it's a meaningful segment. It's a segment that's ripe for innovation, and we hope to deliver that with data in December.

Yatin Suneja, Analyst — Guggenheim

And also, I think, Jason, maybe you and I had discussed it a while back. I think your product, Vito, has a much shorter half-life versus teriflunamide. Can you talk about that dynamic? Is that something that physicians care about, you know, the reversibility of the effect?

Jason Tardio, COO

Certainly. And so just to ground everyone here, the half-life of Vita-fluidomous calcium is about 30 hours compared to, you know, upwards of 16 to 19 days, if you will, for terafluidomide. I mean, the serum half-life of these medicines is vastly different. Our medicine is out of the system within less than 10 days. On terafluidomide, it can stay circulating in the bloodstream for over two years in some patients. And so as per their label, it mandates activated charcoal to rapidly eliminate that. And so when you think about the disease, the disease of young women, that's certainly a differentiator. And we think it's going to allow us to be possibly used in a population where, you know, teriflutamide had limitations.

Yatin Suneja, Analyst — Guggenheim

Got it. So now I want to go back on the safety side, at least in terms of the Ensure 1 and 2 studies. So a couple of things. So I think in October of 2024, there was an interim analysis. And then IDMC said, continue, no change. What is the implication or read through, or how should we read that? And then, you know, I think you are doing a pooled analysis also of different endpoints, whether it's CDI or CDW. What should we be expecting there?

Erik Lundgren, CEO

Yeah. On the interim question, I mean, I think that the IDMC was asked two questions. They unblinded the data and looked at it, and the questions were, is the study futile? Yes or no? No. The answer was no, it's not futile, and then the second was are the powering assumptions that went into the study initially adequate to see a result, or should the sponsor change the protocol and add more power to the study and the correct, and the answer was continue unchanged. That analysis was done at about half of the expected event rate, so about halfway through the study. So what's the read through? I think the read through was they said continue. So, and that's somewhat encouraging, and here we are today, sitting right on the cusp of the final answer. So, I don't think there's much more that you can say than that. It's encouraging. I think that that's a data point. I think the other data points I look to are the emphasis study directly. The baseline demographics are very consistent between the phase two and the phase three enrolled population. And then the other piece, in relapsing MS in particular, gadolinium-enhancing lesions is an extraordinarily effective predictor in phase two of what your clinical outcomes in phase three are going to be when you look at meta-analyses. One of the nice things in MS is you have a lot of studies to do big meta-analyses on, and that has always been consistently the case. So if you see a GAD lesion impact of 50% or more, you're pretty much in safe zone in terms of your primary outcome in the phase three. We had a 76% reduction in GAD lesion, so we were well, well above that sort of general rule of thumb benchmark. So we feel that the phase three is largely de-risked on the primary outcome. And again, I'll knock on wood just because I don't want to tempt the clinical trial guards too much.

Yatin Suneja, Analyst — Guggenheim

Yeah, and then with regard to the pooled progression endpoints, what will be included? How would you define sort of success in these?

Erik Lundgren, CEO

Yeah, so we look at the, because progression in relapsing studies are relatively rare events. You pool the studies together. We're not the only ones to do this. Pretty much every MS program does this in relapsing disease. These are, and then they're hierarchically sort of evaluated, so we're, we've done something a little bit novel with our. Stats plan, and we put an endpoint called net clinical benefit at the top. Net clinical benefit is still using the EDSS scale, which is the gold standard for how progression is followed and measured in MS patients, but it's using a general pairwise comparison, so it's basically getting more out of the same scale. So typically, you're going to look at disability, slowing disability progression is the kind of most standard endpoint utilized. This does that as well, but it's also looking at and valuing if someone stays stable versus a person on the control arm that worsens, that's a win. If someone gets better versus someone that stays stable or gets worse, that's a win. And so you get a lot more data out of it. This is a way of doing these analyses that's been used in oncology studies, and it's being explored in epilepsy studies. And so it's a way of using the gold standard tool, but to just get more signal out of it. So that's where it's going to be.

Yatin Suneja, Analyst — Guggenheim

How would you characterize the phase two to phase three translation from an effect standpoint? I mean, would you expect any deterioration from what you show in emphasis? That's one. And then the second is where we get more pushback from investors is that, look, you have these high efficacy orals, You know, maybe BTKs at some point will play in that mix. Why would somebody give up on the efficacy?

Erik Lundgren, CEO

Yeah. Well, on the read-through, I think you can look at the baseline characteristics, and I think the read-through is we've moved as few variables as you possibly can, and so I think I don't have much to add to that other than I think we've got a pretty clean read-through, we hope, and we would love to see it be in that zone. There's often a little drift off of a phase two to a phase three. It can actually drift on either direction, and I think we have plenty of room based on where we landed in the phase two, 42% risk reduction on relapses, which we think, paired with our safety and tolerability profile, as Jason said, is a best-in-class total risk-benefit package. So we can drift around that a little bit, and I think we're very viable commercially.

Yatin Suneja, Analyst — Guggenheim

Got it, got it. Maybe then... Go on the commercial side. Are there segments of patients that you would target? How large is the market? And how quickly you'll be able to even file for approval?

Jason Tardio, COO

Yeah, I mean, the way that we look at the market is just as a reminder, the relapsing market in the United States is a large market, $70 billion. Today, it's going to grow to be a $25 billion market as we get to the 2030s. The other thing to remember is that there's 300,000 patients treated today with a disease-modifying therapy in relapsing MS. It's a dynamic market, which, you know, approximately 90,000 of those 300,000 are actively looking for something new on an annual basis. These are individuals coming in and initiating therapy. These are individuals that are switching therapies. And so it's not a zero-sum or a one-size-fits-all. The market itself, you know, patients have this 30- or 40-year journey on a disease-modifying therapy. And so what you really want is a medicine that's going to meet that patient at different points in their potential journey, whether that's when they're initiating therapy, whether it's when they're switching therapy, whether it's when they're older. And so the way that we look at the market is that, again, it only takes about a 4% to 5% total market share capture to drive a billion dollars in sales. And so what we do is we look at the value proposition of Vita flutumus calysteum, a uniquely novel mechanistic approach to address both aspects of the disease. As we discussed, a selective inhibitor of DHODH for anti-inflammatory properties, an activator, the only medicine in development that activates NER1 for neuroprotective properties. We've driven great efficacy results to date balanced with what we think could be best in disease safety and tolerability. That's a profile that we think is a winner. And so, again, you asked a little bit about high-efficacy therapies, et cetera. Efficacy isn't, it's certainly an important consideration, but it's not the only attribute that clinicians and patients alike think about when they're making treatment selections. What they're looking at is the holistic picture. So what does efficacy look like compared to safety, compared to tolerability, compared to convenience? If you take all of these factors into place here, again, we believe vitifluidumous calcium is going to offer a highly differentiated medicine, specifically within the oral class. And we think we have a commercial winner on our hands.

Yatin Suneja, Analyst — Guggenheim

Got it.

Erik Lundgren, CEO

And I'd say the other big conversation in the MS community today is how long is too long to be on an anti-CD20? So anti-CD20s have become the dominant sort of mechanistic sort of class, right, anywhere. It's about 50% of the market is on an anti-CD20 today. It's more than that in terms of, like, treatment initiation of a treatment-naive patient, probably 70%, 75% of patients are going to start on an anti-CD20. But the thing is, as Jason said, I mean, people are going to live with, you know, managing their MS for 30 or 40 years. And pretty much all the doctors I talk to, there's not a consensus view, but it's somewhere around three years, between three years and eight years, depending on the doctor and probably depending on the patient across from them, where they're starting to say, that's too much risk now. There's too much risk for opportunistic infection or other issues. And so you're not going to be on an anti-CD20 forever. And if you think about the market today, again, I was a part of launching Ocrevus 10 years ago. It was 10 years ago in March that that medicine launched. It's been the dominant medicine for the last six years. There's a lot of patients that have been on anti-CD20s continuously for a really long time. And there is not a therapy available today that makes sense as a switch to off of an anti-CD20 Because most of the medicines today are either immunosuppressors or have infection risk or have tolerability issues that are going to limit patient acceptance or have PML-associated risk, which is like the big scary side effect in MS. That's where Vito, I think, is such a natural, easy fit right out of the gate. It's a huge need. Every doctor you talk to that has more than a handful of patients in their clinic that they're treating for MS is going to talk about it, and we see an immediate opportunity to slide in there.

Yatin Suneja, Analyst — Guggenheim

Got it. And then how quickly you'll be able to file, and would you want to launch it on your own in the U.S.? What about all you?

Erik Lundgren, CEO

Absolutely. Yeah, we are planning to launch it on our own. And you asked in the beginning about, you know, some of the board changes. And that's really what that was about, is about pivoting to being a commercial company and building ourselves. That's the remit of the board. That's the strategy of the management team. That's what we are building and planning to do. In terms of filing, middle of next year would be the goal for filing. And then, you know, so middle of 28 is sort of the general guidance around launch.

Yatin Suneja, Analyst — Guggenheim

Got it. I think last week you did an R&D day on the progressive MS side. Perhaps would you like to recap, number one, the finding in Caliper and what the path forwarded and the timelines around this phase three study?

Erik Lundgren, CEO

Yep. So Caliper was our phase two study. In progressive MS, as I said, some very exciting findings. I should note, the primary endpoint of that study was whole brain atrophy, and it missed on that, actually. So just to be very transparent about that, it's been subsequently shown in meta-analyses that whole brain atrophy is an incredibly poor predictor of the clinical outcomes. And so it's a little bit of a disappointment that the company had made that the primary endpoint. Nevertheless, there were a bunch of other findings in that study that were incredibly encouraging, both on the imaging side, so certain regions of the brain and volume changes. And then in particular, on an endpoint called slowly expanding lesions, which is thought to be a real marker of this sort of smoldering progressive component of the disease, where we had a nominal statistical benefit on cells. But the clinical outcomes were what really caught my eye, in particular in a subset of patient, large group of the patients, about 85% of the patients, who had no relapses and no GAD-enhancing lesions at baseline, so no evidence of any sort of inflammatory component happening with them. And we saw consistent directional benefit across worsening and improvement in those patients. And if you're seeing that, that is something that has never really been shown before. So this is a nominal finding in a Phase II study. So it's not confirmatory of anything, but it does give us a lot of enthusiasm to charge into a Phase III, which is what we announced last week. This is a study called the Protect MS study, and it's going to be about 1,400 patients looking at a non-active progressive patient population.

Yatin Suneja, Analyst — Guggenheim

And what is the timeline for it?

Erik Lundgren, CEO

So we're initiating it now, first patient randomized, first half of next year, and it will be about a three-year study.

Yatin Suneja, Analyst — Guggenheim

Got it, got it, got it. Maybe then final question. And how is the financial health of the company the capital position?

Erik Lundgren, CEO

Yeah, good. You know, there was a big financing event that you're well aware of, but it was a big pipe that was announced in February of this year. There's a second component of the pipe that has the potential to convert warrants to cash and equity within 30 days of the public disclosure of the Insure 1 and 2 studies. So that's coming up. That would yield another 200 million of cash for us, Which gives us runway into the back half of 28.

Yatin Suneja, Analyst — Guggenheim

Very good, gentlemen, thank you so much. Thank you so much. Thank you.